Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$79.00K$79.00Kderived+71.7% vs Q4 2020 Net Income-$3.46M-$3.46MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,461,000N/M Operating Cash Flowderived-$2,975,000N/M Free Cash Flowderived-$3,016,000N/M Margins · derivedOperating margin-4381.0%+3223.3 pt vs Q4 2020
Net margin-4381.0%+2116.8 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 29, 2022 · 88 d after period end